Endo International plc (ENDP)
(Delayed Data from NSDQ)
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why Is Endo (ENDP) Down 10.6% Since the Last Earnings Report?
by Zacks Equity Research
Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Endo's Troubles Continue to Dent Performance in 2017?
by Zacks Equity Research
2017 will continue to challenging for Endo Pharmaceuticals (ENDP) as the generics base business and the legacy branded pain franchise are expected to decline further.
VIVUS to Regain Commercial Rights for Stendra from Sanofi
by Zacks Equity Research
VIVUS, Inc. (VVUS) recently announced an agreement with Sanofi to reacquire the commercial rights to its erectile dysfunction drug, Stendrain Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia.
BioDelivery (BDSI) Q4 Loss Wider Than Expected; Sales Meet
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) reported loss of 29 cents per share in the fourth quarter of 2016, slightly wider than the Zacks Consensus Estimate of a loss of 28 cents.
Endo's (ENDP) Opana ER's Risk Benefit Evaluated by FDA
by Zacks Equity Research
Endo International plc (ENDP) announced that the FDA Drug Safety Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees had consented that the benefits of reformulated Opana ER no longer outweigh its risks.
New Strong Sell Stocks for March 9th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Why Endo International (ENDP) Could Be Positioned for a Slump
by Zacks Equity Research
One stock that you may want to consider dropping is Endo International plc (ENDP), which has witnessed a significant price decline in the past four weeks.
Endo (ENDP) Beats on Q4 Earnings, Revenues; Guides Low
by Zacks Equity Research
Endo's (ENDP) Q4 results beat expectations but the outlook for 2017 was disappointing and lagged expectations
Endo (ENDP) Q4 Earnings & Revenues Beat Estimates
by Ekta Bagri
Endo (ENDP) surpassed fourth-quarter 2016 earnings
Start the Week with the Best Earnings Charts
by Tracey Ryniec
These earnings giants are crushing it every quarter.
Implied Volatility Surging for Endo International (ENDP) Stock Options
by Zacks Equity Research
Options traders are pricing in a big move for Endo International (ENDP) shares as it has huge implied volatility.
Endo (ENDP) to Post Q4 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Endo International plc (ENDP) is scheduled to report fourth-quarter 2016 results on Feb 28, before the opening bell.
Endo's (ENDP) Ephedrine Sulfate Injection Gets FDA Approval
by Zacks Equity Research
Endo International plc (ENDP) announced that Par Pharmaceutical has received final approval from the FDA regarding its New Drug Application (NDA) for ephedrine sulfate injection.
Endo (ENDP) Restructures Branded Pharmaceutical Unit (revised)
by Zacks Equity Research
Endo International plc (ENDP) announced that it has begun restructuring its corporate and branded pharmaceutical R&D functions in Malvern, PA and Chestnut Ridge, NY.
Endo (ENDP) Restructures its Branded Pharmaceutical Unit
by Zacks Equity Research
Endo International plc (ENDP) announced that it has begun restructuring its corporate and branded pharmaceutical R&D functions in Malvern, PA and Chestnut Ridge, NY.
New Strong Sell Stocks for January 27th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
Is BioMarin (BMRN) Well Poised for Growth in 2017?
by Zacks Equity Research
We issued an updated research report on BioMarin Pharmaceutical Inc. (BMRN) on Jan 25.
Endo (ENDP) Settles Disputes with Federal Trade Commission
by Zacks Equity Research
Endo International plc (ENDP) announced that it has resolved all disputes with the U.S. Federal Trade Commission (FTC).
Implied Volatility Surging for Endo International (ENDP) Stock Options
by Zacks Equity Research
Options traders are pricing in a big move for Endo International (ENDP) shares as it has huge implied volatility.
Endo International (ENDP): Can the Stock Rebound in 2017?
by Zacks Equity Research
Can Endo make a comeback in 2017 seeing that the company is presently in the middle of the drug pricing controversy?
20 States Sue Teva, Mylan & Other Drug Companies for Price Fixing
by Arpita Dutt
The lawsuit and the DoJ antitrust probe pose headline risk for generic companies like Mylan (MYL) and Teva (TEVA).
Generic Stocks Feel Pricing Heat, 1st Charges Filed in DoJ Antitrust Probe
by Arpita Dutt
Key generic drugmakers including Teva (TEVA) saw their shares slip on news that the first charges have been filed in the investigation related to generic drug pricing.
Endo (ENDP) Inks Deal to Return Belbuca Rights to BioDelivery
by Zacks Equity Research
Endo (ENDP) announced that it has entered into an agreement to return the rights for Belbuca to BioDelivery (BDSI).
Mylan (MYL) Stock Falls on Restructuring Plans, Layoffs
by Zacks Equity Research
Mylan (MYL) has revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on integrating acquisitions.
Here's Why Teva Pharmaceutical's (TEVA) Stock Is Down Today
by Ryan McQueeney
Shares of Teva Pharmaceutical Industries (TEVA) slipped over 5.8% in morning trading Tuesday after the company announced a change in upper-level management.